Stem Cells International / 2019 / Article / Tab 1

Review Article

Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System

Table 1

Clinical trials of MSCs on diseases mediated by the immune system.

Trial no.PhaseCommencement yearTargeted diseaseStatusPatient enrollment ()Country

NCT00447460I/II2007Graft vs. host disease (GvHD)Completed [100]15Spain
NCT01522716I2011Unknown (NRP)11Sweden
NCT01764100I2013Completed [101]40Italy
NCT02032446I/IIRecruiting47 (estimated)
NCT02291770III2014Unknown (NRP)130 (estimated)China
NCT02055625I/IISuspended (NRP)11Sweden
NCT02359929I2015Recruiting24 (estimated)USA
NCT01741857I/IISystemic lupus erythematosus (SLE)Completed [102]40China
NCT03171194IActive, not recruiting6 (estimated)USA
NCT03673748II2019SLE/lupus nephritisNot yet recruiting36 (estimated)Spain
NCT00781872I/II2006Multiple sclerosis (MS)Completed [103]20Israel
NCT00395200I/II2008Completed [104, 105]10UK
NCT01730547I/II2013Unknown15 (estimated)Sweden
NCT02495766I/II2015Unknown8 (estimated)Spain
NCT03799718II2019Not yet recruiting20 (estimated)USA
NCT02893306II2012Type 1 diabetes mellitus (T1DM)Unknown (NRP)10Chile
NCT02940418I2017Recruiting20 (estimated)Jordan
NCT03406585I/IIRecruiting24 (estimated)Sweden
NCT02249676II2013Devic syndrome/neuromyelitis opticaCompleted15China
NCT01659762I2012Crohn’s diseaseCompleted [106]16USA

NRP: no results posted.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.